REG - Immupharma PLC - 2021 RESULT OF ANNUAL GENERAL MEETING

ImmuPharmaAnnouncement

28/06/2021 11:05

RNS Number : 3228D
  
Immupharma PLC
  
28 June 2021
  
 

 
 
 
28 June 2021
 
ImmuPharma PLC
("ImmuPharma" or the "Company")
 
2021 RESULT OF ANNUAL GENERAL MEETING - ALL RESOLUTIONS PASSED
 
ImmuPharma PLC (LSE:IMM | Euronext Growth Brussels: ALIMM),  the specialist drug discovery and development company, held its AGM earlier today, in accordance with COVID-19 guidance. The Company is pleased to announce that all resolutions were duly passed.
The results of each resolution were as follows:
 




Resolution


For


% For


Against


% Against


Withheld




1. To receive the accounts of the Company for the year ended 31 December 2020 together with the reports thereon of the directors and auditors of the Company


27,979,197


99.93


20,000


0.07


663,319




2. To re-appoint Dr Stephane Mery as a director of the Company


22,040,754


76.93


6,610,683


23.07


11,079




3. To re-appoint Nexia Smith & Williams as auditors of the Company


28,003,061


99.92


22,348


0.08


637,107




4. That the directors be authorised to allot shares on the basis set out in the Notice of Meeting


27,762,710


99.82


48,844


0.18


850,962




5. To waive pre-emption rights in respect of the issue of the shares on the basis set out in the Notice of Meeting


27,759,210


99.81


52,344


0.19


850,962




 
As at the date of the AGM, the number of issued ordinary shares of the Company was 250,221,2975 shares, which was the total number of shares entitling the holders to attend and vote for or against all resolutions. In accordance with the Company's Articles of Association, every member has one vote for every share held. Votes withheld are not votes in law and have not been counted in the calculation of the proportion of vote "for" or "against" a resolution. Proxy appointments which gave discretion to the Chairman have been included in the "for" total.
 
End
 
 
 




For further information please contact:
 




ImmuPharma PLC (www.immupharma.com)
Tim McCarthy, Chairman


+ 44 (0) 207 152 4080




Dimitri Dimitriou, Chief Executive Officer


 




Lisa Baderoon, Head of Investor Relations


+ 44 (0) 7721 413496
 
 




SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin
 
Stanford Capital Partners (Joint Broker) 
Patrick Claridge
John Howes
Bob Pountney 
 
SI Capital (Joint Broker)
Nick Emerson
 


+44 (0) 203 368 3550
 
 
+44 (0) 203 815 8880
 
 
+44 (0) 1483 413500
 
 




4Reliance (Euronext Growth Listing Sponsor)
Jean-Charles Snoy
 
Degroof Petercam (Liquidity Provider)
Erik De Clippel
 
Backstage Communication
Olivier Duquaine
Gunther De Backer


+32 (0) 2 747 02 60
 
 
+32 (0) 2 287 95 34
 
 
 
+32 (0) 477 504 784
+32 (0) 475 903 909
 




 


 




 




Notes to Editors 
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase 3 trial for Lupuzor™ and commercialise in the US. 
 
For additional information about ImmuPharma please visit www.immupharma.co.uk 
 
ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
RAGDKFBKKBKDBAB